New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Tafinlar (dabrafenib) capsules, for oral use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

Facts of Tafinlar (dabrafenib)

NDA 217514
Drug Name: TAFINLAR
Active Ingredient: DABRAFENIB
Company: NOVARTIS PHARMACEUTICALS CORP
Approval Date: 16-Mar-2023
Dosage Forms And Strengths: Capsules: 50 mg, 75 mg
FDA-approved use on approval date: In combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy

Do you need this medicine in India?

To help you get this medicine – Tafinlar (dabrafenib), a prescription from the Registered Medical Practitioner (RMP) is required. Contact Mr. Tarun at 9891296838 via Call or WhatsApp for availability in India.

Categories ,
Categories ,

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

What Tafinlar is?

  • TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
  • TAFINLAR in combination with trametinib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.

What Dabrafenib is?

Dabrafenib, sold under the brand name Tafinlar, is a medication for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF (V600)-mutated metastatic melanoma.

The US Food and Drug Administration initially approved dabrafenib as a single agent treatment for patients with BRAF V600E mutation-positive advanced melanoma on May 29, 2013.Dabrafenib was approved for use in the European Union in August 2013. In April 2017, the European Union approved the combination of dabrafenib with trametinib for BRAF V600-positive advanced or metastatic non small-cell lung cancer (NSCLC).

TAFINLAR® (dabrafenib) capsules, for oral use Initial U.S. Approval: 2013

See full prescribing information : Click Here

Need Help Getting Medicine? Here’s How We Can Assist You.

Brand Name “Tafinlar” or Generic Name “inavolisib” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surdabrafenibat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.netsouthdelhipharma@gmail.com or  you can call at 9891296838 or WhatsApp at 9891296838

Related Products